Table 1

Demographic and clinical characteristics of patients at baseline

CharacteristicOral MTX (n=417)Subcutaneous MTX (n=249)p Value
Age, years54 (14)51 (15)0.068
Female, %75.173.10.57
Number of comorbidities (0–13)2.2 (1.8)2.5 (1.9)0.041
Smoking status, %0.28
 Never smoked39.145.4
 Ex-smoker42.238.2
 Current smoker18.716.5
Education, %0.23
 Less than high school10.15.6
 High school36.039.8
 College or trade school28.827.7
 University bachelors17.019.7
 Other8.27.2
Symptom duration, months5.2 (2.7)5.2 (2.8)0.61
Seropositive (RF or ACPA), %78.882.00.35
Erosions present on hand or foot X-rays, %24.431.10.08
HAQ-DI (0–3)1.1 (0.69)1.1 (0.69)0.52
DAS-285.5 (1.4)5.5 (1.4)0.86
Starting dose of MTX, mg17.2 (3.8)22.3 (3.6)<0.001
 >20, %5.045.2
 15–20, %56.827.8
 <15, %38.127.0
Concurrent use of systemic glucocorticoids48.051.80.34
 Oral, %24.213.70.001
  Intramuscular or intra-articular, %27.841.4<0.001
Concurrent use of other DMARDs, %53.042.60.009
Concurrent use of biological therapy, %2.20.40.071
  • ACPA, anti-citrullinated protein antibody; DAS-28, Disease Activity Score-28; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; RF, rheumatoid factor.